临床相关性
一级信息 关于临床相关性和缩写列表 |
Clinical Relevance
First level information About Clinical Relevance & List of Abbreviations |
►在常规血清学诊断中非常少见 ►所识别的抗原包括α-辅肌动蛋白和抗黏着斑蛋白;这些自身抗体的特异性免疫检测试剂目前尚未商品化 |
► Found very infrequently in a routine serology diagnostic setting ► Antigens recognized include α-actinin and vinculin; specific immunoassays for these autoantibodies are currently not commercially available |
一级信息参考文献 | First level information references |
无 |
None |
二级信息 | Second level information |
抗α-辅肌动蛋白的自身抗体 ►据报道,在系统性红斑狼疮和狼疮性肾炎中,有交叉反应的抗α-肌动蛋白和抗dsDNA抗体具有致病性 (21) ►据报道,部分抗细胞膜抗体谱是狼疮性肾炎患者的特征;也是无肾脏受累的狼疮肾炎患者区分的一种生物标志物 (22, 23) ►据报道,在相当高比例 (~40%) 的1型自身免疫性肝炎患者中检出该抗体,并且与更严重的疾病、临床和组织病理的疾病活动性、治疗反应的预测性以及和抗ssDNA抗体的双阳性相关联 (24-26) 抗黏着斑蛋白的自身抗体: ►据报道在31例慢性炎性脱髓鞘神经病患者中有2例检出该抗体(27) 注:大多数报道描述了与特异性抗原直接结合的自身抗体 (即,抗原特异性免疫检测法),实际上并未显示与AC-17核型的相关性;这些自身抗体的特异性免疫检测试剂目前尚未商品化。 |
utoantibodies to α-actinin: ► In SLE and lupus nephritis cross-reactive anti-α-actinin and anti-dsDNA autoantibodies have been reported as pathogenic (21) ► Reported as part of the anti-cell membrane antibody spectrum that characterize patients with lupus nephritis; also reported as a biomarker to differentiate patients with lupus nephritis from those without renal involvement (22, 23) ► Reported with relatively high prevalence (~40%) in patients with AIH type 1 and associated with more severe disease, clinical and histological disease activity, predictor of therapeutic response, and double positivity with anti-ssDNA antibodies (24-26) Autoantibodies to vinculin: ► Reported in 2 of 31 patients with chronic inflammatory demyelinating neuropathy (27) Notes: Most reports describe autoantibodies directly binding to specific antigens (i.e. antigen-specific immunoassays) and none actually shows correlations with the AC-17 pattern as such; specific immunoassays for these autoantibodies are currently not commercially available. |
二级信息参考文献 | Second level information references |
21. Zhao Z, Weinstein E, Tuzova M, et al. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential. Arthritis Rheum 2005;52:522-30. 22. Seret G, Canas F, Pougnet-Di Costanzo L, et al. Anti-alpha-actinin antibodies are part of the anti-cell membrane antibody spectrum that characterize patients with lupus nephritis. J Autoimmun 2015;61:54-61. 23. Zhang WH, Pan HF, Zhao XF, et al. Anti-alpha-actinin antibodies in relation to new-onset systemic lupus erythematosus and lupus nephritis. Mol Biol Rep 2010;37:1341-5. 24. Gueguen P, Dalekos G, Nousbaum JB, et al. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. J Clin Immunol 2006;26:495-505. 25. Renaudineau Y, Dalekos GN, Gueguen P, et al. Anti-alpha-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. Clin Rev Allergy Immunol 2008);34:321-5. 26. Zachou K, Oikonomou K, Renaudineau Y, et al. Anti-alpha actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1. Aliment Pharmacol Ther 2012;35:116-25. 27. Beppu M, Sawai S, Satoh M, et al. Autoantibodies against vinculin in patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 2015;287:9-15. |
21. Zhao Z, Weinstein E, Tuzova M, et al. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential. Arthritis Rheum 2005;52:522-30. 22. Seret G, Canas F, Pougnet-Di Costanzo L, et al. Anti-alpha-actinin antibodies are part of the anti-cell membrane antibody spectrum that characterize patients with lupus nephritis. J Autoimmun 2015;61:54-61. 23. Zhang WH, Pan HF, Zhao XF, et al. Anti-alpha-actinin antibodies in relation to new-onset systemic lupus erythematosus and lupus nephritis. Mol Biol Rep 2010;37:1341-5. 24. Gueguen P, Dalekos G, Nousbaum JB, et al. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. J Clin Immunol 2006;26:495-505. 25. Renaudineau Y, Dalekos GN, Gueguen P, et al. Anti-alpha-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. Clin Rev Allergy Immunol 2008);34:321-5. 26. Zachou K, Oikonomou K, Renaudineau Y, et al. Anti-alpha actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1. Aliment Pharmacol Ther 2012;35:116-25. 27. Beppu M, Sawai S, Satoh M, et al. Autoantibodies against vinculin in patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 2015;287:9-15. |
FAQ |
No FAQ received |